Phosphodiesterase inhibitors
By developing 1H-pyrrolo[2,3-b]pyridine-2-formamide derivative compounds, the problem of limitation and insufficient side effects of existing PDE4 inhibitors in the treatment of inflammatory diseases and depression has been solved, and the problem of insufficient selectivity of existing PDE4 inhibitors has been achieved. High selective inhibition of PDE4 significantly reduces inflammatory cytokine production and cocaine-induced behavior, providing a more effective treatment plan.
Patent Information
- Application Number
- CN201980066977.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2018-10-12
- Filing Date
- 2019-10-11
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2039-10-11
AI Technical Summary
The existing PDE4 inhibitors have side effects limitations in the treatment of inflammatory diseases and depression, and are insufficiently selective for specific PDE4 subtypes, making it difficult to effectively treat a variety of diseases.
A new class of 1H-pyrrolo[2,3-b]pyridine-2-formamide derivative compounds were developed to inhibit certain subtypes of PDE4 enzymes, especially PDE4B and PDE4D, through specific structural designs, for the treatment of A variety of diseases and disorders.
These compounds showed high selectivity to PDE4, significantly reduced the production of the inflammatory cytokine TNF-α, reduced cocaine-induced behavior, and had no obvious side effects, providing a more effective treatment regimen.
Smart Images

Figure BDA0003013965880000011 
Figure BDA0003013965880000021 
Figure BDA0003013965880000022
Abstract
Description
Background Art
[0001] Phosphodiesterase 4 (PDE4) is a class of intracellular enzymes that form key components of signal transduction pathways involved in a variety of physiological and pathophysiological conditions. PDE4 is a hydrolase responsible for degrading the second messenger cyclic AMP (cAMP) in many cell types. The PDE4 enzyme family includes four subtypes (PDE4A-D) independently encoded by different genes. PDE4A, PDE4B and PDE4D are present in the brain. PDE4B plays a vital role in the etiology of disorders such as depression and inflammation. The development of novel 1H-pyrrolo[2,3-b]pyridine-2-carboxamide derivatives as selective and effective PDE4 inhibitors is a promising strategy to address the demand for therapies for various diseases and disorders. Summary of the invention
[0002] The present disclosure provides compounds of Formula I:
[0003]
[0004] in
[0005] X, Y and Z are each independently N or CR 3 ;
[0006] R is C each optionally substituted with 1 to 3 R4 0-6 Alkylene-C 6-10 Aryl, C 0-6 Alkylene-5-7 membered heteroaryl, C 0-6 Alkylene-C 3-10 Cycloalkyl, or C 0-6 Alkylene-3-10 membered heterocycloalkyl, wherein the heteroaryl and heterocycloalkyl contain 1-4 ring heteroatoms independently selected from N, O and S;
[0007] R1 is H, C 1-6 alkyl, or a 3-10 membered heterocycloalkyl containing 1-4 ring heteroatoms independently selected from N, O and S, and the heterocycloalkyl is optionally substituted with 1-3 R5;
[0008] R2 is C 1-6 Alkyl, C 0-6 Alkylene-C 3-10 Cycloalkyl, or C containing 1-4 ring heteroatoms independently selected from N, O and S 0-6 Alkylene-3-10 membered heterocycloalkyl, wherein the alkyl, cycloalkyl and heterocycloalkyl are optionally substituted with 1-3 R5;
[0009] or R1 and R2 together with the nitrogen atom to which they are attached form a 3-10 membered heterocycloalkyl ring containing 0-2 additional ring heteroatoms independently selected from N, O and S, wherein said heterocycloalkyl is optionally substituted with 1-3 R6;
[0010] Each R3 is independently H, C 1-6 Alkyl, halogen, CF3, OH, CN, CONR7(R7), SO2NR7R7, OC 1-6 Alkyl, or OC 6-10 Aryl, and the aryl is optionally substituted by 1-3 R5;
[0011] Each R4 is independently C 1-6 Alkyl, halogen, CF3, CN, CONHR7, SO2NR7R7, OC 1-6 Alkyl, or OC 6-10 Aryl;
[0012] Each of R5 and R6 is independently C 1-6 Alkyl, halogen, CF3, CN, OH, or OC 1-6 Alkyl; and
[0013] Each R7 is independently H, C 1-6 Alkyl, C 0-6 Alkylene-C 6-10 Aryl, C 0-6 Alkylene-5-7 membered heteroaryl, C 0-6 Alkylene-C 3-10 Cycloalkyl, or C 0-6 Alkylene-3-10 membered heterocycloalkyl, each aryl, heteroaryl, cycloalkyl and heterocycloalkyl is optionally substituted with 1-3 R5, and the heteroaryl and heterocycloalkyl contain 1-4 ring heteroatoms independently selected from N, O and S.
[0014] In some embodiments, R is C 0-6 Alkylene-C 6-10 Aryl or C 0-6 In some embodiments, R is C 6-10 In some embodiments, R is phenyl. In some embodiments, R is dichlorophenyl. In some embodiments, R is In some embodiments, R is In some embodiments, R is
[0015] Also provided herein are methods of inhibiting PDE4 using the compounds. In one embodiment, the compounds of the present disclosure inhibit one or more specific subtypes of PDE4, including PDE4A, PDE4B, PDE4C, and PDE4D. In some embodiments, the compounds of the present disclosure inhibit PDE4B and / or PDE4D.
[0016] Other aspects of the disclosure include compounds as disclosed herein for use in the preparation of a medicament for treating or preventing a disease or disorder in a subject that can be modulated by PDE4 inhibition, and use of compounds as disclosed herein in a method of treating or preventing a disease or disorder in a subject that can be modulated by PDE4 inhibition. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] Figure 1 Shown are (from left to right) the effects of compounds 8 and 39, control (3-(3-chloro-4-methylphenyl)-N-cyclopropyl-3H-imidazo[4,5-b]pyridine-2-carboxamide), and compounds 7, 18, and 37 on the inhibition of macrophage proinflammatory activity. Bone marrow-derived macrophages were either unstimulated (-) or pretreated with the indicated concentrations of the well-characterized PDE4 inhibitor rolipram or the compounds of interest (1 or 10 μM) for 30 min prior to stimulation with (A) lipopolysaccharide (LPS) (100 ng / ml) or (B) a synthetic lipopeptide (Pam3Cys) (10 μg / ml).
[0018] Figure 2 Compound 8 was shown to significantly reduce cocaine-mediated seeking and intake behaviors in mice.
[0019] Figure 3 Compound 8 was shown to inhibit cocaine-induced hyperlocomotion, whereas compound 8 itself did not show any increase. DETAILED DESCRIPTION
[0020] Provided herein are small molecule inhibitors of PDE4 and methods of use thereof. In one embodiment, the compounds of the present disclosure inhibit one or more specific subtypes of PDE4, including PDE4A, PDE4B, PDE4C, and PDE4D. In some embodiments, the compounds of the present disclosure inhibit PDE4B and / or PDE4D. These compounds can be used to treat a variety of diseases and disorders, including but not limited to cancer, neurodegenerative diseases, addiction, autoimmune disorders, inflammatory disorders, depression and depressive disorders, and anxiety disorders.
[0021] Compounds of the Disclosure
[0022] The present disclosure provides compounds of Formula I:
[0023]
[0024] in
[0025] X, Y and Z are each independently N or CR 3 ;
[0026] R is C each optionally substituted with 1 to 3 R4 0-6 Alkylene-C 6-10 Aryl, C 0-6 Alkylene-5-7 membered heteroaryl, C 0-6 Alkylene-C 3-10 Cycloalkyl, or C 0-6 Alkylene-3-10 membered heterocycloalkyl, wherein the heteroaryl and heterocycloalkyl contain 1-4 ring heteroatoms independently selected from N, O and S;
[0027] R1 is H, C 1-6 alkyl, or a 3-10 membered heterocycloalkyl containing 1-4 ring heteroatoms independently selected from N, O and S, and the heterocycloalkyl is optionally substituted with 1-3 R5;
[0028] R2 is C 1-6 Alkyl, C 0-6 Alkylene-C 3-10 Cycloalkyl, or C containing 1-4 ring heteroatoms independently selected from N, O and S 0-6 Alkylene-3-10 membered heterocycloalkyl, wherein the alkyl, cycloalkyl and heterocycloalkyl are optionally substituted with 1-3 R5;
[0029] or R1 and R2 together with the nitrogen atom to which they are attached form a 3-10 membered heterocycloalkyl ring containing 0-2 additional ring heteroatoms independently selected from N, O and S, wherein said heterocycloalkyl is optionally substituted with 1-3 R6;
[0030] Each R3 is independently H, C 1-6 Alkyl, halogen, CF3, OH, CN, CONR7(R7), SO2NR7R7, OC 1-6 Alkyl, or OC 6-10 Aryl, and the aryl is optionally substituted by 1-3 R5;
[0031] Each R4 is independently C 1-6 Alkyl, halogen, CF3, CN, CONHR7, SO2NR7R7, OC 1-6 Alkyl, or OC 6-10 Aryl;
[0032] Each of R5 and R6 is independently C 1-6 Alkyl, halogen, CF3, CN, OH, or OC 1-6 Alkyl; and
[0033] Each R7 is independently H, C 1-6 Alkyl, C 0-6 Alkylene-C 6-10 Aryl, C 0-6 Alkylene-5-7 membered heteroaryl, C 0-6 Alkylene-C 3-10 Cycloalkyl, or C 0-6 Alkylene-3-10 membered heterocycloalkyl, each aryl, heteroaryl, cycloalkyl and heterocycloalkyl is optionally substituted with 1-3 R5, and the heteroaryl and heterocycloalkyl contain 1-4 ring heteroatoms independently selected from N, O and S.
[0034] As used herein, the term "alkyl" refers to straight chain and branched chain saturated hydrocarbon groups containing from one to thirty carbon atoms, for example, from one to twenty carbon atoms or from one to ten carbon atoms. n Meaning that the alkyl group has "n" carbon atoms. For example, a C4 alkyl group refers to an alkyl group with 4 carbon atoms. A C1-C6 alkyl group refers to an alkyl group with a carbon number covering the entire range (e.g., 1 to 6 carbon atoms) and all sub-ranges (e.g., 1-6, 2-5, 1-4, 3-6, 1, 2, 3, 4, 5 and 6 carbon atoms). Non-limiting examples of alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl (2-methylpropyl) and tert-butyl (1,1-dimethylethyl). Unless otherwise indicated, an alkyl group may be an unsubstituted alkyl group or a substituted alkyl group.
[0035] The term "alkylene" as used herein refers to an alkyl group having a substituent. The alkylene group may be -CH2CH2- or -CH2-. The term C n This means that the alkylene group has "n" carbon atoms. For example, C 1-6 Alkylene refers to an alkylene group having a carbon atom number encompassing the entire range and all subgroups as previously described for an "alkyl" group. Unless otherwise specified, an alkylene group may be unsubstituted or substituted.
[0036] As used herein, the term "cycloalkyl" refers to an aliphatic cyclic hydrocarbon group containing three to ten carbon atoms (e.g., 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms). n It means that the cycloalkyl group has "n" carbon atoms. For example, C5 cycloalkyl refers to a cycloalkyl group having 5 carbon atoms in the ring. 3-10Cycloalkyl refers to carbon atoms covering the entire range (e.g., 3 to 10 carbon atoms) and all subgroups (e.g., 3-9, 3-8, 3-7, 3-6, 3-5, 3-4, 4-9, 4-8, 4-7, 4-6, 4-5, 5-9, 5-8, 5-7, 5-6, 6-9, 6-8, 6-7, 7-9, 7-8, 8-9, 3, 4, 5, 6, 7, 8, 9 and 10 carbon atoms). Non-limiting examples of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl. Unless otherwise indicated, cycloalkyl can be unsubstituted cycloalkyl or substituted cycloalkyl. For example, cycloalkyl can be a cyclobutyl ring substituted by one or two fluoro groups. Cycloalkyl as described herein can be alone or fused with another cycloalkyl, heterocycloalkyl, aryl and / or heteroaryl. The fusion can be, for example, spiral fusion. When a cycloalkyl is fused with another cycloalkyl, unless otherwise indicated, each cycloalkyl can contain three to ten carbon atoms.
[0037] As used herein, the term "heterocycloalkyl" is defined similarly to cycloalkyl, except that the ring contains one to four heteroatoms independently selected from oxygen, nitrogen and sulfur. In particular, the term "heterocycloalkyl" refers to a ring containing a total of three to ten atoms (e.g., three to seven or five to ten), wherein 1, 2, 3 or 4 atoms in those atoms are heteroatoms independently selected from the group consisting of oxygen, nitrogen and sulfur, and the atoms remaining in the ring are carbon atoms. Non-limiting examples of heterocycloalkyl include azetidine, piperidine, pyrazolidine, tetrahydrofuran, tetrahydropyran, dihydrofuran, morpholine, etc. Unless otherwise indicated, heterocycloalkyl can be unsubstituted heterocycloalkyl or substituted heterocycloalkyl. For example, heterocycloalkyl can be an azetidine ring substituted by one or two fluoro groups.
[0038] As used herein, the term "aryl" refers to a monocyclic aromatic group, such as phenyl. Unless otherwise indicated, aryl can be unsubstituted or substituted by one or more and particularly one to four groups independently selected from, for example, alkyl, halogen, CF3, CN, OH, amide, sulfonamide, O-alkyl or O-aryl. Aryl can be independent (e.g., phenyl), or fused with another aryl (e.g., naphthyl, anthracenyl), cycloalkyl (e.g., tetrahydronaphthyl), heterocycloalkyl and / or heteroaryl. Exemplary aryl includes, but is not limited to, phenyl, chlorophenyl, dichlorophenyl, methylphenyl, methoxyphenyl, trifluoromethylphenyl, 2,4-methoxychlorophenyl, etc.
[0039] As used herein, the term "heteroaryl" refers to a monocyclic aromatic ring having 5 to 7 total ring atoms and containing one to four heteroatoms selected from nitrogen, oxygen and sulfur atoms in the aromatic ring. Unless otherwise indicated, heteroaryl can be unsubstituted or substituted by one or more and particularly one to four groups independently selected from, for example, alkyl, halogen, CF3, CN, OH, amide, sulfonamide, O-alkyl or O-aryl. Examples of heteroaryl include, but are not limited to, thienyl, furyl, pyridyl, pyrrolyl, oxazolyl, triazine, triazolyl, isothiazolyl, isoxazolyl, imidazolyl, pyrazinyl, pyrimidinyl, thiazolyl and thiadiazolyl.
[0040] In some cases, at least one of X, Y and Z is CR3. In some cases, at least one of X, Y and Z is N. In some cases, each of X, Y and Z is CR3. In some cases, each R3 is independently H, C 1-6 Alkyl, halogen, CF3, OH, CN or OC 1-6 In some cases, at least one R3 is H. In some cases, at least one R3 is C 1-6 In some cases, at least one R3 is halogen. In some cases, at least one R3 is CF3. In some cases, at least one R3 is OH. In some cases, at least one R3 is CN. In some cases, at least one R3 is -OC 1-6 In some cases, X, Y, and Z are each CH.
[0041] In some cases, R is C 0-6 Alkylene-C 6-10 Aryl or C 0-6 In some cases, R is C 1-6 Alkylene-C 6-10 Aryl or C 1-6 In some cases, R is C1 alkylene-C 6-10 In some cases, R is C 6-10 In some cases, R is C 6-10 In some cases, R is phenyl. In some cases, R is dichlorophenyl. In some cases, R is In some cases, R is In some cases, R is
[0042] In some cases, R is substituted with 1 to 3 R4. In some cases, R is substituted with 1 R4. In some cases, R is substituted with 2 R4. In some cases, R is substituted with 3 R4.
[0043] In some cases, each R4 is independently C 1-6 Alkyl, OC 1-6 In some cases, at least one R4 is halogen. In some cases, each R4 is halogen. In some cases, at least one R4 is fluorine. In some cases, at least one R4 is chlorine. In some cases, at least one R4 is C 1-6 In some cases, at least one R4 is methyl. In some cases, at least one R4 is OC 1-6 In some cases, at least one R4 is CN or OMe. In some cases, at least one R4 is CN. In some cases, at least one R4 is OMe.
[0044] In some cases, R1 is H. In some cases, R1 is C 1-6 alkyl.
[0045] In some cases, R2 is C 0-6 Alkylene-C 3-10 Cycloalkyl or C 0-6 In some cases, R2 is C 3-10 In some cases, R2 is C 3-5 In some cases, R2 is cyclopropyl. In some cases, R2 is cyclobutyl. In some cases, R2 is
[0046] In some cases, R2 is replaced by 1-3 R5. In some cases, R2 is replaced by 1 R5. In some cases, R2 is replaced by 2 R5. In some cases, R2 is replaced by 3 R5. In some cases, at least one R5 is halogen. In some cases, each R5 is halogen. In some cases, at least one R5 is fluorine. In some cases, each R5 is fluorine.
[0047] In some cases, R1 and R2 form a 3-10-membered heterocycloalkyl ring together with the nitrogen atom to which they are attached. In some cases, R1 and R2 form a 3-membered heterocycloalkyl ring together with the atom to which they are attached. In some cases, R1 and R2 form a 4-membered heterocycloalkyl ring together with the atom to which they are attached. In some cases, R1 and R2 form a 5-membered heterocycloalkyl ring together with the atom to which they are attached. In some cases, R1 and R2 form a 6-membered heterocycloalkyl ring together with the atom to which they are attached. In some cases, R1 and R2 form a 7-membered heterocycloalkyl ring together with the atom to which they are attached. In some cases, R1 and R2 form an 8-membered heterocycloalkyl ring together with the atom to which they are attached. In some cases, R1 and R2 form a 9-membered heterocycloalkyl ring together with the atom to which they are attached. In some cases, R1 and R2 form a 10-membered heterocycloalkyl ring together with the atom to which they are attached. In some cases, the heterocycloalkyl ring is unsubstituted. In some cases, the heterocycloalkyl ring is replaced by 1-3 R6. In some cases, the heterocycloalkyl ring is replaced by 1 R6. In some cases, the heterocycloalkyl ring is replaced by 2 R6. In some cases, the heterocycloalkyl ring is replaced by 3 R6.
[0048] In some cases, R6 is halogen or CF3. In some cases, at least one R6 is halogen. In some cases, each R6 is halogen. In some cases, R6 is fluorine. In some cases, at least one R6 is CF3.
[0049] In some cases, N(R1)(R2) is
[0050] Also provided are compounds listed in Table A or pharmaceutically acceptable salts thereof. Also provided are uses of compounds listed in Table A or pharmaceutically acceptable salts thereof.
[0051] Table A
[0052]
[0053]
[0054]
[0055]
[0056]
[0057]
[0058]
[0059]
[0060] The compounds disclosed herein may be in the form of pharmaceutically acceptable salts. As used herein, the term "pharmaceutically acceptable salts" refers to those salts suitable for contact with tissues of humans and lower animals without excessive toxicity, irritation, allergic reactions, etc., within the scope of reasonable medical judgment, and commensurate with reasonable benefit / risk ratios. Pharmaceutically acceptable salts are well known in the art. For example, SM Berge et al. describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1-19, which is incorporated herein by reference. Pharmaceutically acceptable salts of the compounds of the present invention include salts derived from suitable inorganic and organic acids and bases. Examples of pharmaceutically acceptable non-toxic acid addition salts are amino salts formed with inorganic acids (such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid) or organic acids (such as acetic acid, trifluoroacetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid) or by using other methods used in the art (such as ion exchange). Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, glutamate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate, and the like. Salts of compounds containing carboxylic acids or other acidic functional groups can be prepared by reaction with a suitable base. Such salts include, but are not limited to, alkali metals, alkaline earth metals, aluminum salts, ammonium, N + (C 1-4The present invention also contemplates the quaternization of any basic nitrogen-containing group of the compounds disclosed herein. Water-soluble or oil-soluble or dispersible products can be obtained by such quaternization. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Additional pharmaceutically acceptable salts include non-toxic ammonium, quaternary ammonium and amine cations formed when appropriate using counterions such as halides, hydroxides, carboxylates, sulfates, phosphates, nitrates, lower alkyl sulfonates and aryl sulfonates.
[0061] Synthesis of the Disclosed Compounds
[0062] The compounds disclosed herein can be prepared in various ways using commercially available starting materials, compounds known in the literature or from easily prepared intermediates, by using standard synthetic methods and steps known to those skilled in the art or in view of the teachings herein. Standard synthetic methods and procedures for organic molecule preparation and functional group transformation and manipulation can be obtained from relevant scientific literature or from standard textbooks in the art. Although not limited to any one or several sources, classic texts (such as Smith, MB, March, J., March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 5th edition, John Wiley & Sons: New York, 2001; and Greene, TW, Wuts, PGM, Protective Groups in Organic Synthesis, 3rd edition, John Wiley & Sons: New York, 1999) are useful and recognized organic synthesis reference textbooks known to those skilled in the art. For example, the compounds disclosed herein can be synthesized by solid phase synthesis techniques, including those described in Merrifield, J. Am. Chem. Soc. 1963; 85:2149; Davis et al., Biochem. Intl. 1985; 10:394-414; Larsen et al., J. Am. Chem. Soc. 1993; 115:6247; Smith et al., J. Peptide Protein Res. 1994; 44:183; O'Donnell et al., J. Am. Chem. Soc. 1996; 118:6070; Stewart and Young, Solid Phase Peptide Synthesis, Freeman (1969); Finn et al., The Proteins, 3rd ed., Vol. 2, pp. 105-253 (1976); and Erickson et al., The Proteins, 3rd ed., Vol. 2, pp. 105-253 (1976). Proteins, 3rd Edition, Vol. 2, pp. 257-527 (1976). The following descriptions of synthetic methods are intended to illustrate, but not to limit, the general procedures for preparing the compounds of the present disclosure.
[0063] The synthetic methods disclosed herein can tolerate a wide variety of functional groups; therefore, a variety of substituted starting materials can be used. The methods provide substantially the desired final compound at or near the end of the entire process, but in some cases may require further conversion of the compound into a pharmaceutically acceptable salt, ester or prodrug thereof.
[0064] Generally, compounds of Formula I can be synthesized according to Scheme 1 or 2.
[0065] Solution 1
[0066]
[0067] Compounds having structure c can be synthesized using the procedures shown in Schemes 1 or 2.
[0068] In Scheme 1, the methyl ester a is treated with a derivative of a substituent R containing a leaving group (e.g., boronic acid) and an appropriate reagent (e.g., chloral hydrate, ammonium hydroxide, and concentrated sulfuric acid) to produce a derivative compound b. For example, in the case where R is an aryl group (e.g., 3,4-dichlorophenyl), a is treated with an aryl boronic acid (e.g., (3,4-dichlorophenyl)boronic acid) under coupling conditions (e.g., treatment with copper (II) acetate and pyridine in dichloromethane at room temperature for 12 hours) to produce compound b, wherein R is an aryl group (e.g., 3,4-dichlorophenyl). b is hydrolyzed under appropriate conditions (e.g., treatment with sodium hydroxide in a mixture of methanol and water), followed by treatment with an amine having a NHR1R2 structure under appropriate coupling conditions (e.g., propanephosphonic anhydride (T3P) and diisopropylethylamine (DIPEA) in dimethylformamide (DMF) at room temperature for 30 minutes to 4 hours) to produce a compound of Formula I having structure c. Appropriate coupling conditions will be known to those skilled in the art, but are contemplated to include, but are not limited to, transition metal catalyzed addition reactions such as copper catalyzed addition reactions (eg, Lam coupling).
[0069] The conditions of Scheme 2 are the same as those of Scheme 1, except that hydrolysis and amine coupling can be performed to form amide d prior to coupling with the R group to form a compound of Formula I having structure c.
[0070] Additional synthetic procedures for preparing compounds disclosed herein can be found in the Examples section.
[0071] Drug formulations, dosages and routes of administration
[0072] Also provided are pharmaceutical formulations comprising a compound as described herein (eg, a compound of Formula I or a pharmaceutically acceptable salt of said compound) and a pharmaceutically acceptable excipient.
[0073] The compounds described herein can be administered to a subject in a therapeutically effective amount (e.g., an amount sufficient to prevent or alleviate the symptoms of a disorder associated with abnormal PDE4 activity). These compounds can be administered alone or as part of a pharmaceutically acceptable composition or formulation. In addition, the compounds can be administered all at once, multiple times, or delivered generally uniformly over a period of time. It should also be noted that the dosage of the compound can vary over time.
[0074] The specific administration regimen for a particular subject will depend in part on the compound, the amount of the compound administered, the route of administration, and the cause and extent of any side effects. The amount of the compound administered to a subject (e.g., a mammal, such as a human) according to the disclosure should be sufficient to affect the desired response within a reasonable time frame. The dosage generally depends on the route, time, and frequency of administration. Therefore, clinicians titrate the dosage and change the route of administration to obtain the best therapeutic effect, and conventional range-finding techniques are known to those of ordinary skill in the art.
[0075] Merely by way of illustration, the method includes administering, for example, about 0.1 mg / kg up to about 100 mg / kg of the compound or more, depending on the factors mentioned above. In other embodiments, the dosage range is from 1 mg / kg to about 100 mg / kg; or 5 mg / kg to about 100 mg / kg; or 10 mg / kg to about 100 mg / kg. Some conditions require prolonged treatment, which may or may not result in multiple administrations followed by administration of a lower dose of the compound. If desired, the dose of the compound may be administered in two, three, four, five, six or more sub-doses at appropriate intervals throughout the day, optionally in unit dosage form. The treatment period will depend on the specific circumstances and may last from one day to several months.
[0076] Suitable methods for administering physiologically acceptable compositions (such as pharmaceutical compositions including compounds disclosed herein (e.g., compounds of Formula I)) are well known in the art. Although more than one approach can be used to administer the compound, a specific approach can provide a more direct and more effective response than another approach. Depending on the circumstances, the pharmaceutical composition comprising the compound is administered or instilled into the body cavity, absorbed by the skin or mucous membranes, ingested, inhaled, and / or introduced into the circulation. For example, in some cases, it is desirable that the pharmaceutical composition including the medicament be delivered orally, delivered by intravenous, intraperitoneal, intracerebral (in the substance), intraventricular, intramuscular, intraocular, intraarterial, intraportal, intralesional, intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, local, sublingual, urethral, vaginal, or rectal means, by injection, delivered by a sustained release system or by an implant. If desired, the compound is administered regionally via intrathecal administration, intracerebral (in the substance), intraventricular administration, or intraarterial or intravenous administration, thereby feeding into the area of interest. Alternatively, the composition is administered topically via an implanted membrane, sponge, or another suitable material into which the desired compound has been absorbed or encapsulated. When an implant device is used, in one aspect, the device is implanted in any suitable tissue or organ, and the delivery of the desired compound is, for example, via diffusion, timed release bolus, or continuous administration.
[0077] In order to facilitate administration, in various aspects, the compound is formulated into a physiologically acceptable composition comprising a carrier (e.g., vehicle, adjuvant or diluent). The specific carrier used is limited by chemical-physical considerations (such as solubility and insufficient reactivity with the compound) and the route of administration. Physiologically acceptable carriers are well known in the art. Illustrative drug forms suitable for injection purposes include sterile aqueous solutions or dispersions and sterile powders for temporary preparation of sterile injection solutions or dispersions (e.g., see U.S. Patent No. 5,466,468). Injectable formulations are further described in the following documents: for example, Pharmaceutics and Pharmacy Practice, JB Lippincott Co., Philadelphia. Pa., Banker and Chalmers, pp. 238-250 (1982) and ASHP Handbook on Injectable Drugs, Toissel, 4th edition, pp. 622-630 (1986)). On the one hand, the pharmaceutical composition comprising the compound is placed in a container together with packaging material, and the packaging material provides instructions for the use of such pharmaceutical composition. Typically, such instructions include a tangible expression describing the concentration of the reagent, and the relative amount of the excipient component or diluent (e.g., water, saline or PBS) that may be needed to reconstruct the pharmaceutical composition in certain embodiments.
[0078] Compositions suitable for parenteral injection can include physiologically acceptable sterile aqueous or non-aqueous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstructing as sterile injection solutions or dispersions. Examples of suitable aqueous and non-aqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (propylene glycol, polyethylene glycol, glycerol, etc.), suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters (such as ethyl oleate). For example, by using a coating (such as lecithin), by maintaining the desired particle size in the case of a dispersion, and by using a surfactant, suitable fluidity can be maintained.
[0079] These compositions may also contain adjuvants such as preservatives, wetting agents, emulsifiers and dispersants. Microbial contamination may be prevented by the addition of various antibacterial and antifungal agents (e.g., parabens, chlorobutanol, phenol, sorbic acid, etc.). It may also be desirable to include isotonic agents such as sugars, sodium chloride, etc. The absorption of injectable pharmaceutical compositions may be prolonged by the use of agents that delay absorption (e.g., aluminum monostearate and gelatin).
[0080] Solid dosage forms for oral administration include capsules, tablets, powders and granules. In such solid dosage forms, the active compound is mixed with: at least one inert conventional excipient (or carrier), such as sodium citrate or dicalcium phosphate or (a) fillers or extenders, such as starch, lactose, sucrose, mannitol and silicic acid; (b) binders, such as carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and gum arabic; (c) humectants, such as glycerol; (d) disintegrants, such as agar-agar, calcium carbonate, potato tapioca starch, alginic acid, certain complex silicates and sodium carbonate; (a) solution retarders, such as paraffin; (f) absorption promoters, such as quaternary ammonium compounds; (g) wetting agents, such as cetyl alcohol and glyceryl monostearate; (h) adsorbents, such as kaolin and bentonite; and (i) lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium lauryl sulfate or mixtures thereof. In the case of capsules and tablets, the dosage form may also contain buffering agents.Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols.
[0081] Solid dosage forms such as tablets, dragees, capsules, pills and granules can be prepared with coatings and shells, such as enteric coatings and other coatings well known in the art. Solid dosage forms may also contain opacifiers. In addition, solid dosage forms may be embedded compositions that release one or more of the active compounds in a delayed manner in a specific part of the intestinal tract. Examples of embedded compositions that can be used are polymeric substances and waxes. The active compound may also be in microcapsule form, optionally containing one or more excipients.
[0082] Oral liquid dosage forms include pharmaceutically acceptable emulsions, solutions, suspensions, syrups and elixirs. In addition to the active compound, the liquid dosage form may contain an inert diluent commonly used in the art, such as water or other solvents, solubilizers and emulsifiers, such as, for example, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils, specifically cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil, glycerol, tetrahydrofurfuryl alcohol, polyethylene glycol and fatty acid esters of sorbitan, or mixtures of these substances, and the like.
[0083] In a particular instance, the compound or mixture is orally administered, such as by mixing with distilled water. In another example, the test compound or mixture is intravenously administered, such as in saline or distilled water. In some instances, treatment with the test compound can be a single dose or repeated dose. The test compound can be administered approximately every 6 hours, approximately every 12 hours, approximately every 24 hours (every day), approximately every 48 hours, approximately every 72 hours, or approximately once a week. The treatment of repeated doses can continue for a period of time, for example, for about 1 week to 12 months, such as about 1 week to about 6 months or about 2 weeks to about 3 months or about 1 to 2 months. The administration of the compound can also continue indefinitely. The dosage of the test compound is from about 0.1mg / kg to about 400mg / kg, such as about 1mg / kg to about 300mg / kg, about 2mg / kg to 200mg / kg, about 10mg / kg to about 100mg / kg, about 20mg / kg to about 75mg / kg, or about 25mg / kg to about 50mg / kg.
[0084] In addition to such inert diluents, the composition may also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring and perfuming agents. In addition to the active compounds, suspensions may contain suspending agents such as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar and tragacanth, or mixtures of these substances, etc.
[0085] Compositions for rectal administration may be suppositories which may be prepared by mixing a compound of the present disclosure with a suitable non-irritating excipient or carrier such as cocoa butter, polyethylene glycol or a suppository wax which is solid at ordinary temperatures but liquid at body temperature and therefore melts in the rectum or vaginal cavity and releases the active ingredients.
[0086] The compositions used in the methods of the invention can be formulated into micelles or liposomes. Such formulations include sterically stabilized micelles or liposomes and sterically stabilized mixed micelles or liposomes. Such formulations can facilitate intracellular delivery, as the lipid bilayers of liposomes and micelles are known to fuse with the plasma membrane of cells and deliver the entrapped contents into intracellular compartments.
[0087] After formulation, the solution will be administered in a manner compatible with the dosage formulation and in a therapeutically effective amount. The formulation can be easily administered in various dosage forms (such as injectable solutions, drug release capsules, etc.). For example, for parenteral administration in aqueous solution, if necessary, the solution should be appropriately buffered and the liquid diluent first made isotonic with sufficient saline or glucose. These specific aqueous solutions are particularly suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration.
[0088] The frequency of administration will depend on the pharmacokinetic parameters and administration route of the medicament. According to the administration route and the required dosage, those skilled in the art will determine the optimal drug formulation. See, for example, Remington's Pharmaceutical Sciences, 18th edition (1990) Mack Publishing Co., Easton, PA, pages 1435-1712, which are incorporated herein by reference. Such formulations may affect the physical state, stability, in vivo release rate and in vivo clearance rate of the administered medicament. Depending on the administration route, suitable dosage can be calculated according to body weight, body surface area or organ size. A person of ordinary skill in the art can routinely optimize the calculation required for determining an appropriate therapeutic dose without excessive experimentation, especially according to the dosage information and analysis disclosed herein, and the pharmacokinetic data observed in animal or human clinical trials.
[0089] The precise dose to be used depends on several factors, including the host (whether in veterinary or human medicine), the nature and severity of the condition (e.g., disease or disorder) being treated, the mode of administration, and the specific active substance used. The compound can be administered by any conventional route, specifically enterally, and in one aspect, orally in tablet or capsule form. The compound administered may be in free form or in pharmaceutically acceptable salt form, as appropriate, for use as a medicament, particularly for prophylactic or therapeutic treatment of the target disease. These measures will slow the rate of progression of the disease condition and assist the body in reversing the direction of progression in a natural manner.
[0090] It should be understood that the pharmaceutical compositions and methods of treatment of the present invention can be used in the fields of human medicine and veterinary medicine. Thus, in one aspect, the subject to be treated is a mammal. In another aspect, the mammal is a human.
[0091] In jurisdictions that prohibit patenting of methods practiced on humans, the meaning of "administering" a composition to a human subject shall be limited to prescribing a controlled substance to be self-administered by a human subject by any technique (e.g., oral, inhalation, topical application, injection, insertion, etc.). The broadest reasonable interpretation consistent with the law or regulation defining patentable subject matter is intended. In jurisdictions that do not prohibit patenting of methods practiced on humans, "administering" a composition includes both methods practiced on humans and also the foregoing activities.
[0092] How to use
[0093] In this way, the compounds described herein regulate PDE4A, PDE4B or PDE4D, for example, the compounds trigger or inhibit the biological activity mediated by PDE4A, PDE4B or PDE4D, such as regulating the intracellular cAMP concentration. In various embodiments, the compound is a PDE4 inhibitor, for example, the compound changes, inhibits or prevents one or more biological activities mediated by PDE4. In some embodiments, the compound shows a higher selectivity to a PDE4 isoform than other PDE4 isoforms. In some embodiments, the compound is selective to PDE4B and / or PDE4D. In some embodiments, the compound has a higher selectivity to PDE4B than to other PDE4 isoforms. In some embodiments, the compound has a higher selectivity to PDE4D than to other PDE4 isoforms.
[0094] The compounds disclosed herein are particularly advantageous for treating diseases or disorders caused by aberrant expression or activity of PDE4. The incidence and / or intensity of diseases or disorders associated with aberrant expression or activity of PDE4 can be reduced by administering the compounds disclosed herein.
[0095] Aberrant expression or activity of PDE4 is associated with a number of adverse conditions. These include, for example, cancer, neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, or ALS), multiple sclerosis, chronic traumatic encephalopathy (CTE), traumatic brain injury (TBI), Batten Disease (including but not limited to infantile-onset CLN1 disease, juvenile-onset CLN1 disease, late infantile-onset CLN2 disease, later-onset CLN2 disease, juvenile-onset CLN3 disease, adult-onset CLN4 disease, late infantile-onset CLN5 disease variant, late infantile-onset CLN6 disease variant, adult-onset CLN6 disease, late infantile-onset CLN7 disease variant, CLN8 disease, or CLN10 disease), addiction, autoimmune disorders, inflammatory disorders, chronic obstructive pulmonary disease (COPD), depression and depressive disorders, anxiety disorders, schizophrenia, attention deficit hyperactivity disorder, asthma, rheumatoid arthritis, stroke, autism, Huntington's disease, atopic dermatitis, psoriatic arthritis, and plaque psoriasis.
[0096] Cancers contemplated in the disclosed methods of use include, but are not limited to, ovarian cancer, breast cancer, prostate cancer, colon cancer, liver cancer, brain cancer, kidney cancer, lung cancer, leukemia, lymphoma, multiple myeloma, thyroid cancer, bone cancer, esophageal cancer, and pancreatic cancer.
[0097] The compounds of formula I and the compounds disclosed in Table A show high selectivity for inhibition of PDE4 (e.g., PDE4B inhibition) and / or inhibition of macrophage pro-inflammatory activity. In this way, the compounds disclosed herein can be used as therapeutic agents for inflammatory diseases. Inflammatory diseases considered in the disclosed methods of use include, but are not limited to, arthritis, rheumatoid arthritis, atherosclerosis, multiple sclerosis, asthma, inflammatory bowel disease, Crohn's disease, gastritis, pancreatitis, systemic inflammatory response syndrome, and chronic inflammatory demyelinating polyradiculoneuritis. In some cases, the compounds described herein can be used to reduce or prevent inflammatory diseases in human subjects suffering from, for example, chronic obstructive pulmonary disease (COPD), asthma, rheumatoid arthritis, psoriasis, or psoriatic arthritis.
[0098] Addictions contemplated in the disclosed methods of use include, but are not limited to, cocaine addiction, methamphetamine addiction, heroin addiction, and alcohol addiction. In some embodiments, the addiction is cocaine addiction.
[0099] PDE4 selective inhibitors have previously been used in a variety of disease states, for example, as a therapeutic strategy for treating COPD and psoriatic arthritis. However, PDE4 inhibitor therapy has been hindered by dose-limiting side effects such as nausea and vomiting. It is assumed that these side effects are partially related to the inhibition of PDE4D isoforms. Selective inhibition of PDE4 isoforms other than PDE4D (e.g., selective inhibition of PDE4B) may be a useful strategy for treating or preventing inflammatory diseases, with little or no dose-limiting side effects.
[0100] The disclosed methods include methods for treating diseases or disorders (e.g., inflammatory diseases or addiction) that can be regulated by inhibiting PDE4, the methods comprising administering to a subject a compound that inhibits PDE4. In some instances, the methods disclosed herein include using a compound that reduces TNFα production. Also provided herein is a method for regulating PDE4 (e.g., PDE4B and / or PDE4D, particularly PDE4B) in a cell. In some embodiments, the method involves contacting a cell with a compound disclosed herein (e.g., a compound of Formula I or a compound as shown in Table A). Cell contact can occur in vitro or in vivo. In some cases, cell contact occurs in vitro. In other cases, cell contact occurs in vivo. Therefore, the present disclosure includes administering one or more compounds described herein to a subject (such as a person) in need. In some embodiments, the subject suffers from a disease or disorder associated with the abnormal activity of PDE4, as described above.
[0101] It will be appreciated that the methods and compositions described herein for treating cancer (including administering compounds that inhibit PDE4) are applicable to methods of treating other diseases associated with PDE4 activity (such as those described above). Methods for evaluating the effectiveness of test compounds for treating such diseases in cells, appropriate animal models, or affected subjects are known to those skilled in the art.
[0102] Also provided herein is the use of a compound disclosed herein in the preparation of a medicament for treating a disease or disorder associated with PDE4 activity.
[0103] The disclosure herein will be more readily understood by reference to the following examples.
[0104] Example
[0105] The following examples are provided for illustration and are not intended to limit the scope of the present disclosure.
[0106] Synthetic procedures for compounds of formula I
[0107] General Experimental Procedures All reagents were purchased from commercial sources and used without further purification.
[0108] Example 1: Compound of formula (I)
[0109] General reaction scheme of compound 1-15:
[0110]
[0111] 1-(3,4-Dichlorophenyl)-1H-pyrrolo[2,3-b]pyridine-2-carboxylic acid methyl ester (B). A reaction flask was charged with A (0.055 g; 0.27 mmol), 3-chloro-4-methylphenylboronic acid (0.093 g; 0.54 mmol), cupric acetate (0.074 g; 0.41 mmol), CH2Cl2 (5 mL) and then pyridine (0.088 mL; 1.1 mmol). The reaction mixture was stirred at room temperature overnight. The mixture was filtered through a short pad of celite. The filtrate was concentrated and purified on silica gel (eluted with 0-50% EtOAc / hexane, then 0-5% MeOH / dichloromethane) to give the desired product. LCMS: R T =2.92min, >98% at 215 and 254nm, m / z=321.0[M+H] + ; 1H NMR (499MHz, DMSO-d6) δ8.43(d,J=4.3Hz,1H),8.26(d,J=7.8Hz,1H),7.83(s,1H),7.7 8(d,J=8.5Hz,1H),7.51(s,1H),7.46(d,J=8.9Hz,1H),7.37–7.29(m,1H),3.77(s,3H).
[0112] 1-(3,4-Dichlorophenyl)-1H-pyrrolo[2,3-b]pyridine-2-carboxylic acid (C). To a solution of B (0.12 g; 0.36 mmol) in MeOH (6.0 mL) was added a pre-dissolved solution of NaOH (0.36 mL; 0.72 mmol) in H2O (1.0 mL). The reaction mixture was stirred at room temperature overnight. The reaction mixture was then concentrated in vacuo and acidified with 1N HCl (pH≈4). The aqueous mixture was extracted with EtOAc, dried (MgSO4) and concentrated to give the corresponding acid derivative, which was used without further purification. LCMS: R T =2.560min,>98% at 215 and 254nm, m / z=306.9[M+H] + ; 1 H NMR (499MHz, DMSO-d6) δ13.19(s,1H),8.41(d,J=4.5Hz,1H),8.24(d,J=7.9Hz,1H),7.81(d, J=2.5Hz, 1H), 7.77 (d, J=8.5Hz, 1H), 7.45 (q, J=3.3, 2.0Hz, 2H), 7.30 (dd, J=8.0, 4.6Hz, 1H).
[0113] General amine coupling procedure:
[0114] In the vial and screw cap vial equipped with magnetic stirring bar, C (0.10 g; 0.60 mmol), amine (0.44 mL; 3.1 mmol), diisopropylethylamine (0.047 mL; 0.67 mmol), CH2Cl2 (10.0 mL) were loaded and stirred for about 5 minutes. Propylphosphonic anhydride (T3P, 50 wt.% in ethyl acetate) (0.55 mL was added; 9.6 mmol), and the reaction was stirred until LCMS analysis showed that the starting material was significantly consumed (30 min). The crude reaction mixture was diluted with water (15 mL), and the mixture was extracted with dichloromethane (4x15 mL). The organic layer combined was dried over Na2SO4, and evaporated under reduced pressure to give a crude product, which was purified by silica gel flash column chromatography with a gradient of 0-100% ethyl acetate in hexane (using silica gel / DCM dry method loading), to give the corresponding amide product 1-15.
[0115] N-cyclopropyl-1-(3,4-dichlorophenyl)-1H-pyrrolo[2,3-b]pyridine-2-carboxamide (1). LCMS: R T =2.597min,>98% at 215 and 254nm, m / z=346.0[M+H] + ; 1 H NMR (499MHz, CDCl3) δ8.44(d,J=4.7Hz,1H),8.02(d,J=7.8Hz,1H),7.67–7.48(m,2H),7.33(d,J=8.5Hz,1H),7.21(dd ,J=7.8,4.3Hz,1H),6.97(s,1H),6.25(s,1H),2.82(dq,J=7.4,4.0Hz,1H),0.86(d,J=6.8Hz,2H),0.62–0.51(m,2H). 13 C NMR (126MHz, CDCl3) δ162.16,149.59,146.62,136.16,133.04,132.85,132.42,130.58,129.80,127.28,119.07,118.10,104.54,22.85,6.93.
[0116] N-cyclobutyl-1-(3,4-dichlorophenyl)-1H-pyrrolo[2,3-b]pyridine-2-carboxamide (2). LCMS: R T =2.771, >98% at 215 and 254 nm, m / z = 360.0 [M+H] + ; 1H NMR (499MHz, CDCl3) δ8.40(t,J=12.9Hz,1H),8.03(d,J=7.8Hz,1H),7.57(d,J=8.5Hz,1H),7.52(d,J=14.7Hz,1H),7.30(d,J=8.1Hz,1H),7. 20(dd,J=7.5,4.7Hz,1H),7.05(d,J=23.5Hz,1H),4.46–4.38(m,1H),2.35(d,J=8.0Hz,2H),1.94–1.84(m,2H),1.74(dd,J=11.1,5.2Hz,2H). 13 C NMR (126MHz, CDCl3) δ159.98,149.12,146.04,136.05,133.42,132.78,132 .36,130.96,130.57,129.67,127.20,118.01,104.66,44.84,30.89,15.13.
[0117] 1-(3,4-Dichlorophenyl)-N-(3-fluorocyclobutyl)-1H-pyrrolo[2,3-b]pyridine-2-carboxamide (3). LCMS: R T =2.696min,>98% at 215 and 254nm, m / z=378.0[M+H] + ; 1 H NMR (499MHz, CDCl3) δ8.51–8.37(m,1H),8.05(dd,J=8.2,1.6Hz,1H),7.62(d,J=8.4H z,1H),7.56(d,J=2.4Hz,1H),7.34(dd,J=8.4,2.4Hz,1H),7.23(dd,J=7.9,4.6Hz,1H) ,7.03(s,1H),6.19(s,1H),5.22(ddt,J=55.9,6.5,3.1Hz,1H),4.64(dt,J=8.6,6.0Hz ,1H),2.72(dddt,J=17.8,12.0,8.2,3.7Hz,2H),2.39(ddt,J=20.4,13.4,6.0Hz,2H). 13 C NMR (126MHz, CDCl3) δ160.55,149.64,146.82,136.06,132.95,132.54,130.64,13 0.62,129.75,127.21,118.99,118.20,104.82,87.23,85.63,41.77,38.30,38.12.
[0118] 1-(3,4-dichlorophenyl)-N-(3,3-difluorocyclobutyl)-1H-pyrrolo[2,3-b]pyridine-2-carboxamide (4). LCMS: R T =2.777min,>98% at 215 and 254nm, m / z=396.0[M+H] + ; 1 H NMR (499MHz, CDCl3) δ8.46(dd,J=4.5,1.6Hz,1H),8.06(dd,J=7.9,1.7Hz,1H),7.62(d,J=8.4Hz,1H),7.55(d,J=2.3Hz,1H),7.33(dd,J=8.3,2.3Hz,1H ),7.24(dd,J=7.9,4.6Hz,1H),7.07(s,1H),6.40–6.24(m,1H),4.40(td,J= 7.6, 6.7, 3.7Hz, 1H), 3.09 (ddt, J=11.7, 8.5, 2.9Hz, 2H), 2.63–2.44 (m, 2H). 13 C NMR (126MHz, CDCl3) δ160.70,149.68,146.98,135.98,133.00,132.68,132.30,130.78,130.78,130. 67,129.81,127.27,118.95,118.27,105.09,53.43,43.33,43.14,42.96,35.36,35.29,35.24,35.17.
[0119] 1-(3,4-Dichlorophenyl)-N-(furan-2-ylmethyl)-1H-pyrrolo[2,3-b]pyridine-2-carboxamide (5). LCMS: R T =2.744min,>98% at 215 and 254nm, m / z=386.0[M+H] + ; 1 H NMR(499MHz, CDCl3)δ8.43(dd,J=4.7,1.6Hz,1H),8.00(dt,J=8.1,1.3Hz,1H),7.64–7.49(m,2H),7.29(dd,J=8.6,2.4Hz,1H),7 .20(dd,J=7.9,4.7Hz,1H),7.02(s,1H),6.60(d,J=5.6Hz,1H),6.38–6.28(m,1H),6.24(d,J=3.2Hz,1H),4.54(d,J=5.6Hz,2H). 13C NMR (126MHz, CDCl3) δ160.62,150.54,149.65,146.71,142.42,136.12,132.86,132.81,1 32.33,130.63,130.55,129.72,127.19,119.06,118.13,110.57,107.88,105.09,36.61.
[0120] Azetidin-1-yl(1-(3,4-dichlorophenyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)methanone (6). LCMS: R T =2.631 min, >98% at 215 and 254 nm, m / z=346.0 [M+H] + ; 1 H NMR(499MHz, CDCl3)δ8.44(dd,J=4.6,1.5Hz,1H),8.04(dd,J=7.9,1.6Hz,1H),7.67–7.52(m,2H),7.34(d d,J=8.5,2.4Hz,1H),7.22(dd,J=7.9,4.7Hz,1H),6.89(s,1H),4.50–4.10(m,5H),2.39(p,J=7.8Hz,2H). 13 C NMR (126MHz, CDCl3) δ161.83,149.11,146.36,136.42,132.71,132.08,130.94,130.46,130.44,129.47,126.99,119.32,117.93,105.51,16.05.
[0121] (1-(3,4-dichlorophenyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)(3-fluoroazetidin-1-yl)methanone (7). LCMS: R T =2.636, >98% at 215 and 254 nm, m / z = 364.0 [M+H] + ; 1 H NMR (499MHz, CDCl3) δ8.46(d,J=4.6Hz,1H),8.06(dd,J=7.8,1.7Hz,1H),7.71–7.53(m,2H),7.32(dd,J=8.4,2. 4Hz, 1H), 7.23 (dd, J = 7.9, 4.7Hz, 1H), 6.91 (s, 1H), 5.40 (ddq, J = 56.6, 6.7, 3.4Hz, 1H), 4.52 (d, J = 37.9Hz, 4H). 13C NMR (126MHz, CDCl3) δ162.08,149.34,146.91,136.23,132.79,132.31,130.62, 130.51,130.16,129.60,127.09,119.09,118.15,106.18,82.84,81.21,29.72.
[0122] (1-(3,4-dichlorophenyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)(3,3-difluoroazetidin-1-yl)methanone (8). LCMS: R T =2.764min,>98% at 215 and 254nm, m / z=382.0[M+H] + ; 1 H NMR (499MHz, CDCl3) δ8.48 (dd, J = 4.8, 1.6 Hz, 1H), 8.07 (dd, J = 7.9, 1.6 Hz, 1H), 7.67–7.52 (m, 2H), 7.36–7.21 (m, 2H), 6.93 (s, 1H), 4.58 (s, 4H). 13 C NMR (126MHz, CDCl3) δ162.13,162.10,162.07,149.48,147.34,136.08,132.85,132.49,1 30.81,130.55,129.73,129.51,127.17,118.94,118.33,117.35,115.17,112.98,106.75.
[0123] (1-(3,4-dichlorophenyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)(3,3-difluoroazetidin-1-yl)methanone (9). LCMS: R T =2.830min, >98% at 215 and 254nm, m / z=414.0[M+H] + ; 1 H NMR (499MHz, CDCl3) δ8.46 (dd, J=4.6, 1.7Hz, 1H), 8.05 (dd, J=7.9, 1.7Hz, 1H), 7.64–7.54 (m, 2H), 7.38–7. 27(m,1H),7.23(dd,J=7.9,4.7Hz,1H),6.92(s,1H),4.61–4.14(m,4H),3.37(dtd,J=14.1,8.7,5.3Hz,1H). 13C NMR (126MHz, CDCl3) δ162.11,149.31,146.98,136.14,132.81,132.29,130.70,130.53,12 9.64,129.52,127.00,119.10,118.23,106.25,51.89,48.00,32.98,32.73,32.47,32.21.
[0124] (1-(3,4-dichlorophenyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)(1-oxa-6-azaspiro[3.5]nonan-6-yl)methanone (10). LCMS: R T =2.685min,>98% at 215 and 254nm, m / z=416.0[M+H] + ; 1 H NMR (499MHz, CDCl3) δ8.52–8.36(m,1H),8.03(d,J=7.7Hz,1H),7.75(d,J=90.1Hz,1H),7.64–7.40(m,2H),7.22(dd,J=7.9,4.7Hz,1H),6.80(dd,J=30 .8,9.8Hz,1H),4.79–4.44(m,2H),4.45–4.06(m,2H),3.42(ddd,J=60.5,2 2.2,10.6Hz,2H),3.26–2.95(m,1H),2.50–2.20(m,2H),2.07–1.53(m,4H). 13 C NMR (126MHz, CDCl3) δ162.47,145.52,135.72,132.96,131.63,130.72,130.10,128.47,1 26.00,119.63,117.94,104.13,103.45,82.26,65.27,64.56,56.68,36.48,30.20,20.67.
[0125] (1-(3,4-dichlorophenyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)(1,1-dioxythiomorpholino)methanone (11). LCMS: R T =2.505min, >98% at 215 and 254nm, m / z=424.0[M+H] + ; 1H NMR (499MHz, DMSO-d6) δ8.40(dd,J=4.6,1.6Hz,1H),8.20(dd,J=7.9,1.6Hz,1H),7.89(d,J=2.4Hz,1H),7.78( d,J=8.6Hz,1H),7.43(dd,J=8.6,2.5Hz,1H),7.32(dd,J=7.9,4.6Hz,1H),4.04(s,4H),3.27(t,J=5.3Hz,4H). 13 C NMR(126MHz,DMSO-d6)δ161.73,148.39,145.99,136.52,131.99,131.51,131.33,131.1 0,130.37,129.17,127.52,119.46,118.66,105.00,51.33,40.59,40.42,40.26,40.09.
[0126] (1-(3,4-dichlorophenyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)(7-azaspiro[3.5]nonan-7-yl)methanone (12). LCMS: R T =3.208min, >98% at 215 and 254nm, m / z=414.1[M+H] + ; 1 H NMR (499MHz, CDCl3) δ8.40(d,J=5.3Hz,1H),8.00(d,J=7.9Hz,1H),7.69(d,J=2.4Hz,1H),7.58(d,J=8.6Hz,1H),7.44(dd,J=8.6,2.4Hz,1H),7.20 (dd,J=7.9,4.7Hz,1H),6.74(s,1H),3.46(d,J=127.2Hz,4H),1.91(q,J= 7.9, 6.9Hz, 2H), 1.78 (dt, J = 16.7, 7.9Hz, 4H), 1.59 (s, 2H), 1.37 (s, 2H). 13 C NMR (126MHz, CDCl3) δ161.84,148.02,145.31,135.79,133.52,132.97,131.63,130.75,130.0 4,129.96,128.38,125.86,119.76,117.94,103.15,44.32,39.18,37.83,36.85,31.35,15.01.
[0127] (1-(3,4-dichlorophenyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)(6-azaspiro[3.4]octan-6-yl)methanone (13). LCMS: R T =3.024 min, >98% at 215 and 254 nm, m / z = 400.0 [M+H] + ; 1 H NMR (499MHz, CDCl3) δ8.42(t,J=4.9Hz,1H),8.02(t,J=7.9Hz,1H),7.66(d,J=2.4Hz,1H),7.57(d,J=8.5Hz,1H),7.43(dd,J=8.7 ,2.4Hz,1H),7.22(dd,J=8.1,4.5Hz,1H),6.84(d,J=9.3Hz,1H),3.57(t,J=7.1Hz,1H),3.41(d,J=2.6Hz,2H),2.06–1.79(m,9H). 13 C NMR (126MHz, CDCl3) δ161.55,145.66,136.11,134.13,132.90,131.62,130.67,130.15,128.42,125.92,119 .67,117.95,103.77,103.71,59.79,57.23,47.19,45.12,44.73,43.56,37.62,36.02,30.92,30.56,15.93.
[0128] (1-(3,4-dichlorophenyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)(6-azaspiro[3.4]octan-6-yl)methanone (14). A solution of tert-butyl 2-(1-(3,4-dichlorophenyl)-1H-pyrrolo[2,3-b]pyridine-2-carbonyl)-2,7-diazaspiro[4.5]decane-7-carboxylate (0.035 g, 0.066 mmol) in CH2Cl2 (5.0 mL) was treated with TFA (0.65 mL) for 12 h. The solvent was removed in vacuo, and the crude product was dissolved in 10% MeOH / CH2Cl2, washed with saturated aqueous NaHCO3, brine, dried (MgSO4), and concentrated. The crude product was purified on silica gel (eluted with 0-15% MeOH / DCM) to give the desired product, compound 14. LCMS: R T =1.996min,>98% at 215 and 254nm, m / z=429.1[M+H] + ; 1H NMR (499MHz, CDCl3) δ8.40 (dd, J=11.1, 4.7Hz, 1H), 8.00 (d, J=7.9Hz, 1H), 7.70–7.5 2(m,2H),7.40(ddd,J=25.0,8.5,2.5Hz,1H),7.19(td,J=8.7,4.7Hz,1H),6.88(d,J= 21.0Hz,1H),4.38(s,3H),3.61(dtt,J=24.3,15.2,8.8Hz,3H),3.40(dd,J=33.6,12. 2Hz, 1H), 3.14–2.64 (m, 4H), 1.95 (ddt, J=52.3, 13.5, 6.9Hz, 1H), 1.85–1.60 (m, 2H). 13 C NMR (126MHz, CDCl3) δ148.30,145.77,136.21,133.70,132.75,131.55,130.70,130.28,1 28.52,126.16,119.51,117.92,104.21,57.15,54.89,46.86,44.17,35.18,33.79,32.82.
[0129] (1-(3,4-dichlorophenyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)(2,7-diazaspiro[3.5]nonane-2-yl)methanone (15). A solution of tert-butyl 2-(1-(3,4-dichlorophenyl)-1H-pyrrolo[2,3-b]pyridine-2-carbonyl)-2,7-diazaspiro[3.5]nonane-7-carboxylate (0.055 g, 0.087 mmol) in CH2Cl2 (5.0 mL) was treated with TFA (0.65 mL) for 12 h. The solvent was removed in vacuo, and the crude product was dissolved in 10% MeOH / CH2Cl2, washed with saturated aqueous NaHCO3, brine, dried (MgSO4), and concentrated. The crude product was purified on silica gel (eluted with 0-15% MeOH / DCM) to give the desired product, compound 15. LCMS: R T =1.939 min, >98% at 215 and 254 nm, m / z = 415.0 [M+H] + ; 1H NMR(499MHz, CDCl3) δ8.43(d,J=4.6Hz,1H),8.02(d,J=7.9Hz,1H),7.67–7.51(m,2H),7.33(dd,J=8.5,2.4Hz,1H ),7.20(dd,J=8.0,4.6Hz,1H),6.90(s,1H),4.01(s,2H),3.84(s,3H),2.88(d,J=8.0Hz,4H),1.90–1.70(m,4H). 13 C NMR (126MHz, CDCl3) δ162.20,149.14,146.62,136.45,132.65,132.02,130.63,130.49,130.4 7,129.45,127.00,119.22,118.08,105.85,62.70,58.40,50.55,48.65,42.61,34.91,34.30.
[0130] General procedure for compounds 16-43.
[0131]
[0132] 1-(3-Chloro-4-methylphenyl)-N-cyclopropyl-1H-pyrrolo[2,3-b]pyridine-2-carboxamide (16). LCMS: R T =1.939 min, >98% at 215 and 254 nm, m / z = 415.0 [M+H] + ; 1 H NMR (499MHz, CDCl3) δ8.46(d,J=4.0Hz,1H),8.06(dd,J=7.8,1.6Hz,1H),7.55(t,J=8.2Hz,1H),7.33(dd,J=9.4,2 .4Hz,1H),7.22(ddd,J=11.3,8.4,3.8Hz,2H),6.92(s,1H),5.39(ddq,J=56.6,6.4,3.2Hz,1H),4.68–4.16(m,5H). 13 C NMR (126MHz, CDCl3) δ162.12,162.10,158.77,156.77,149.26,146.86,136.60,136.53,130.64,130.56,130 .23,124.07,124.04,120.91,120.77,119.15,118.17,116.45,116.27,106.22,99.98,82.82,81.18,29.72.
[0133] 1-(3-Chloro-4-methylphenyl)-N-cyclobutyl-1H-pyrrolo[2,3-b]pyridine-2-carboxamide (17). LCMS: R T =2.723min, >98% at 215 and 254nm, m / z=340.0[M+H] + ; 1 H NMR (499MHz, CDCl3) δ8.39(d,J=4.2Hz,1H),8.03(d,J=7.8Hz,1H),7.43(s,1H),7.39(d,J=8.0Hz,1H),7.29–7.24(m,2H),7.18(d d,J=7.7,4.8Hz,1H),7.06(s,1H),4.46–4.39(m,1H),2.32(m,2H),2.21(s,3H),1.83–1.75(m,2H),1.70(dt,J=11.3,4.6Hz,2H). 13 C NMR (126MHz, CDCl3) δ159.99,149.28,145.99,136.51,135.19,134.67,133.67,131 .27,130.83,128.35,126.13,119.32,117.74,104.91,44.77,30.92,19.85,15.11.
[0134] 1-(4-chloro-3-methylphenyl)-N-(3-fluorocyclobutyl)-1H-pyrrolo[2,3-b]pyridine-2-carboxamide (18). LCMS: R T =2.644min,>98% at 215 and 254nm, m / z=358.0[M+H] + ; 1 H NMR (499MHz, CDCl3) δ8.49–8.40(m,1H),8.08–7.98(m,1H),7.49–7.38(m,2H),7.29(d,J=2.2Hz,1H),7.24–7.14(m,1H),7.07(s,1H),6. 08(d,J=6.2Hz,1H),5.13(dq,J=56.1,4.0,2.5Hz,1H),4.65–4.53(m,1H),2.75–2.58(m,2H),2.47(s,3H),2.28(td,J=14.0,7.0Hz,2H). 13C NMR (126MHz, CDCl3) δ160.58,146.51,141.19,136.62,135.93,135.21,134.83,133.81 ,131.39,130.73,128.45,126.18,117.90,105.27,41.50,38.27,38.09,20.60,19.94.
[0135] (1-(3-chloro-4-methylphenyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)(3-fluoroazetidin-1-yl)methanone (20). LCMS: R T =2.588min,>98% at 215 and 254nm, m / z=344.0[M+H] + ; 1 H NMR(499MHz, CDCl3)δ8.46(s,1H),8.05(d,J=8.0Hz,1H),7.47(s,1H),7.39(d,J=7.9Hz,1H),7.27(s,1H),7 .22(d,J=7.1Hz,1H),6.90(s,1H),5.37(dtt,J=56.5,6.4,3.5Hz,1H),4.40(d,J=89.2Hz,5H),2.46(s,3H). 13 C NMR (126MHz, CDCl3) δ162.43,146.71,136.08,135.47,134.44,131.07,130.57 ,130.42,128.02,125.80,119.07,117.83,105.63,82.85,81.21,29.71,19.93.
[0136] 1-(4-Chloro-3,5-difluorophenyl)-N-cyclopropyl-1H-pyrrolo[2,3-b]pyridine-2-carboxamide (21). LCMS: R T =2.572 min, >98% at 215 and 254 nm, m / z=348.0 [M+H] + ; 1 H NMR (499MHz, CDCl3) δ8.50–8.38(m,1H),8.02(dd,J=7.7,1.6Hz,1H),7.23(dd,J=7.9,4.6Hz,1H),7.17–7. 07(m,2H),6.95(s,1H),6.33(s,1H),2.84(dq,J=7.2,3.6Hz,1H),0.88(d,J=6.8Hz,2H),0.66–0.57(m,2H). 13C NMR (126MHz, CDCl3) δ162.02,159.60,159.57,157.61,157.57,149.54,146.80, 136.31,132.84,130.65,119.06,118.32,112.40,112.21,104.65,22.88,6.91.
[0137] 1-(4-Chloro-3,5-difluorophenyl)-N-cyclobutyl-1H-pyrrolo[2,3-b]pyridine-2-carboxamide (22). LCMS: R T =2.742 min, >98% at 215 and 254 nm, m / z=362.0 [M+H] + ; 1 H NMR (499MHz, CDCl3) δ8.45(s,1H),8.04(d,J=7.8Hz,1H),7.24(dd,J=7.6,4.6Hz,1H),7.14(d,J=7.4Hz,2H),7 .00(s,1H),6.28(d,J=6.3Hz,1H),4.56–4.45(m,1H),2.47–2.39(m,2H),2.00–1.91(m,3H),1.83–1.76(m,2H). 13 C NMR (126MHz, CDCl3) δ159.67,159.61,159.57,157.61,157.57,149.37,146.54, 136.25,133.18,130.72,118.31,112.33,112.12,104.59,45.05,31.18,15.18.
[0138] (1-(4-chloro-3,5-difluorophenyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)(3-fluoroazetidin-1-yl)methanone (25). LCMS: R T =2.611min, >98% at 215 and 254nm, m / z=366.0[M+H] + ; 1 H NMR (499MHz, CDCl3) δ8.47 (dd, J=4.7, 1.6Hz, 1H), 8.06 (dd, J=7.9, 1.6Hz, 1H), 7.25 (dd, J=8.0 ,4.7Hz,1H),7.20–7.08(m,2H),6.92(s,1H),5.43(dtt,J=56.4,6.3,3.4Hz,1H),4.50(s,4H). 13C NMR (126MHz, CDCl3) δ161.74,159.58,159.54,157.58,157.54,149.22,147.04,136.42,136.32,130.78, 129.97,119.15,118.39,112.24,112.22,112.19,112.07,112.04,112.02,106.63,82.82,81.18,29.71.
[0139] 1-(4-cyano-3,5-difluorophenyl)-N-cyclopropyl-1H-pyrrolo[2,3-b]pyridine-2-carboxamide (26). LCMS: R T =2.444min,>98% at 215 and 254nm, m / z=339.0[M+H] + ; 1 H NMR (499MHz, CDCl3) δ8.52–8.40(m,1H),8.06(d,J=7.6Hz,1H),7.28(s,3H),7.23(d,J=9. 0Hz, 2H), 7.00 (s, 1H), 6.41 (s, 1H), 2.87 (s, 1H), 0.92 (d, J = 6.8Hz, 2H), 0.75–0.59 (m, 2H). 13 C NMR (126MHz, CDCl3) δ163.89,161.88,149.27,147.02,132.49,130.94,119.34,118.93,112.10,111.92,109.02,105.95,22.99,6.97.
[0140] 1-(4-cyano-3,5-difluorophenyl)-N-cyclobutyl-1H-pyrrolo[2,3-b]pyridine-2-carboxamide (27). LCMS: R T =2.612 min, >98% at 215 and 254 nm, m / z=353.0 [M+H] + ; 1 H NMR(499MHz, CDCl3)δ8.45(d,J=4.1Hz,1H),8.08(dd,J=19.3,7.8Hz,1H),7.30–7.26(m,1H),7.23(d,J=8.5Hz,2H),7.0 4(s,1H),6.41(s,1H),4.50(dt,J=15.8,7.9Hz,1H),2.54–2.38(m,2H),2.08–1.97(m,2H),1.81(dt,J=18.2,8.9Hz,3H). 13C NMR (126MHz, CDCl3) δ163.88,161.80,159.52,149.11,146.78,143.29,132.86, 130.99,119.47,118.90,111.95,111.80,109.05,105.85,45.18,31.14,15.21.
[0141] 1-(4-cyano-3,5-difluorophenyl)-N-(3-fluorocyclobutyl)-1H-pyrrolo[2,3-b]pyridine-2-carboxamide (28). LCMS: R T =2.542min, >98% at 215 and 254nm, m / z=371.1[M+H] + ; 1 H NMR (499MHz, DMSO-d6) δ9.08(d,J=6.9Hz,1H),8.41(d,J=4.5Hz,1H),8.26(d,J=7.8Hz,1H),7.63(d,J=9.6Hz,2H),7.41(s,1H) ,7.34(dd,J=7.9,4.7Hz,1H), 5.29(dddd,J=56.7,10.3,6.4,4.0Hz,1H), 4.44(dtd,J=11.4,7.2,5.7,2.9Hz,1H), 4.05(s,4H). 13 C NMR(126MHz,DMSO-d6)δ163.25,163.20,161.22,161.16,160.16,160.07,149.13,146.67,144.69,133.35,131.61,11 9.61,119.21,113.05,112.85,109.91,107.09,89.88,88.12,86.54,48.19,48.02,47.85,40.99,37.77,37.60,31.11.
[0142] 1-(4-cyano-3,5-difluorophenyl)-N-(3,3-difluorocyclobutyl)-1H-pyrrolo[2,3-b]pyridine-2-carboxamide (29). LCMS: R T =2.623min, >98% at 215 and 254nm, m / z=389.0[M+H] + ; 1H NMR (499MHz, CDCl3) δ8.49(s,1H),8.09(d,J=7.8Hz,1H),7.36–7.29(m,1H),7.22(d,J=8.7Hz,2H),7. 11(s,1H),6.59–6.38(m,1H),4.42(d,J=9.8Hz,1H),3.24–3.00(m,2H),2.63(td,J=13.7,5.9Hz,2H). 163.94,161.86,160.42,149.37,143.20,131.81,131.12,119.14,112.11,111.93,108.98,106.57,43.29,43.11,42.92,35.58,35.51,35.46,35.39.
[0143] 2,6-Difluoro-4-(2-(3-fluoroazetidine-1-carbonyl)-1H-pyrrolo[2,3-b]pyridin-1-yl)benzonitrile (30). LCMS: R T =2.490min,>98% at 215 and 254nm, m / z=357.0[M+H] + ; 1 H NMR(499MHz, CDCl3) δ8.47(dd,J=4.9,1.6Hz,1H),8.08(dd,J=8.0,1.6Hz,1H),7.36–7.26(m ,1H),7.26–7.20(m,2H),6.97(s,1H),5.46(ddt,J=56.3,6.1,2.9Hz,1H),4.82–4.20(m,3H). 13 CNMR (126MHz, CDCl3) δ163.90,163.85,161.82,161.77,161.29,161.27,148.97,147.25,143.35,131.07 ,129.65,119.43,118.97,112.00,111.97,111.83,111.80,109.00,107.94,91.41,82.80,81.16,29.72.
[0144] 1-(4-Chlorophenyl)-N-cyclopropyl-1H-pyrrolo[2,3-b]pyridine-2-carboxamide (31). LCMS: R T =2.404min,>98% at 215 and 254nm, m / z=312.0[M+H] + ; 1H NMR (499MHz, CDCl3) δ8.44(dd,J=4.7,1.6Hz,1H),8.02(dd,J=8.0,1.6Hz,1H),7.51(d,J=8.2Hz,2H),7.40(d,J=8.3Hz,2H) ,7.20(dd,J=7.9,4.7Hz,1H),7.02(s,1H),6.09(s,1H),2.80(dq,J=7.4,3.7Hz,1H),0.89–0.78(m,2H),0.56–0.44(m,2H). 13 C NMR (126MHz, CDCl3) δ162.26,149.70,146.53,135.28,134.13,133.26,130.47,1 29.37,129.08,119.07,117.87,104.75,77.29,77.23,77.03,76.78,22.81,6.90.
[0145] 1-(4-Chlorophenyl)-N-cyclobutyl-1H-pyrrolo[2,3-b]pyridine-2-carboxamide (32). LCMS: R T =2.582min, >98% at 215 and 254nm, m / z=326.0[M+H] + ; 1 H NMR (499MHz, CDCl3) δ8.44(d,J=4.2Hz,1H),8.04(d,J=7.8Hz,1H),7.52(d,J=8.3Hz,2H),7.41(d,J=8.4Hz,2H),7.27(d,J=13.4Hz,1H),7.2 0(dd,J=7.7,4.7Hz,1H),7.06(s,1H),6.06(d,J=6.1Hz,1H),4.57–4.42(m,1H),2.37(d,J=6.5Hz,2H),1.88–1.78(m,3H),1.78–1.70(m,3H). 13 C NMR (126MHz, CDCl3) δ159.88,149.57,146.32,135.26,134.17,133.56,130.54,129.41,129.09,119.19,117.84,104.77,44.88,31.17,15.14.
[0146] 1-(4-Chloro-3-fluorophenyl)-N-cyclopropyl-1H-pyrrolo[2,3-b]pyridine-2-carboxamide (33). LCMS: R T=2.482 min, >98% at 215 and 254 nm, m / z=330.0 [M+H] + ; 1 H NMR(499MHz, CDCl3)δ8.45(s,1H),8.03(d,J=7.8Hz,1H),7.54(t,J=7.6Hz,1H),7.37–7 .13(m,3H),6.98(s,1H),6.25(s,1H),2.82(s,1H),0.86(d,J=7.1Hz,2H),0.58(s,2H). 13 C NMR (126MHz, CDCl3) δ162.18,158.82,156.84,149.52,146.56,136.50,136.43, 133.05,130.64,124.34,119.10,118.12,116.72,116.54,104.62,22.86,6.92.
[0147] 1-(4-Chloro-3-fluorophenyl)-N-cyclobutyl-1H-pyrrolo[2,3-b]pyridine-2-carboxamide (34). LCMS: R T =2.643min, >98% at 215 and 254nm, m / z=344.0[M+H] + ; 1 H NMR (499MHz, CDCl3) δ8.45(d,J=3.3Hz,1H),8.06(t,J=12.3Hz,1H),7.55(t,J=8.2Hz,1H),7.31(d,J=9.2Hz,1H),7.23(t,J =6.4Hz,2H),6.19(d,J=5.8Hz,1H),4.49(dq,J=16.0,8.0Hz,1H),2.45–2.35(m,2H),1.96–1.86(m,2H),1.82–1.71(m,2H). 13 C NMR (126MHz, CDCl3) δ159.79,156.84,149.41,146.39,133.39,130.66,130.66,124.2 9,118.08,116.68,116.50,116.41,104.55,77.28,77.02,76.77,44.97,31.19,15.27.
[0148] (1-(4-chloro-3-fluorophenyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)(3-fluoroazetidin-1-yl)methanone (37). LCMS: R T=2.521min, >98% at 215 and 254nm, m / z=348.0[M+H] + ; 1 H NMR (499MHz, CDCl3) δ8.46(d,J=4.0Hz,1H),8.06(dd,J=7.8,1.6Hz,1H),7.55(t,J=8.2Hz,1H),7.33(dd,J=9.4,2 .4Hz,1H),7.22(ddd,J=11.3,8.4,3.8Hz,2H),6.92(s,1H),5.39(ddq,J=56.6,6.4,3.2Hz,1H),4.68–4.16(m,5H). 13 C NMR (126MHz, CDCl3) δ162.12,162.10,158.77,156.77,149.26,146.86,136.60,136.53,130.64,130.56,130 .23,124.07,124.04,120.91,120.77,119.15,118.17,116.45,116.27,106.22,99.98,82.82,81.18,29.72.
[0149] (3-Fluoroazetidin-1-yl)(1-(4-methoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)methanone (38). LCMS: R T =2.274 min, >98% at 215 and 254 nm, m / z=326.0 [M+H] + ; 1 H NMR(499MHz, CDCl3)δ8.46(dd,J=4.8,1.6Hz,1H),8.04(dd,J=8.0,1.7Hz,1H),7.45–7.35(m,2H),7.19(dd,J=7.9,4.7Hz,1H),7.10 –7.02(m,2H),6.90(s,1H),5.32(dtd,J=56.5,6.2,3.2Hz,1H),4.42(ddd,J=18.9,12.0,6.7Hz,2H),4.35–4.16(m,2H),3.89(s,3H). 13 C NMR (126MHz, CDCl3) δ162.95,159.06,149.45,146.40,131.08,130.30,129.49,128.39,119.10,117.55,114.35,105.02,82.81,81.18,55.47.
[0150] (1-(5-chloro-6-methoxypyridin-3-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl)(3-fluoroazetidin-1-yl)methanone (39). LCMS: R T =2.460min, >98% at 215 and 254nm, m / z=361.0[M+H] + ; 1 H NMR (499MHz, CDCl3) δ8.46(d,J=5.0Hz,1H),8.11(d,J=2.3Hz,1H),8.06(d,J=8.0Hz,1H),7.82(d,J=2.3Hz,1H),7 .23(dd,J=7.9,4.5Hz,1H),6.90(s,1H),5.41(ddt,J=56.4,6.1,3.0Hz,1H),4.37(d,J=133.2Hz,6H),4.10(s,3H). 13 C NMR (126MHz, CDCl3) δ161.98,161.96,158.79,149.74,146.98,143.25,137.97,130.61,13 0.08,127.68,118.98,118.13,117.80,105.98,82.85,81.22,77.30,77.05,76.79,54.69.
[0151] (1-(3-Fluoro-4-methoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)(3-fluoroazetidin-1-yl)methanone (40). LCMS: R T =2.330min, >98% at 215 and 254nm, m / z=344.1[M+H] + ; 1 H NMR(499MHz, CDCl3)δ8.46(d,J=4.3Hz,1H),8.04(dd,J=8.0,1.7Hz,1H),7.26–7.15(m,3H),7.10(t,J =8.9Hz,1H),6.89(s,1H),5.36(ddt,J=56.6,6.2,3.0Hz,1H),4.47(s,3H),4.32(s,3H),3.96(s,3H). 13C NMR (126MHz, CDCl3) δ162.49,152.80,150.83,149.52,147.55,147.46,146.67,130 .41,129.54,123.51,119.01,117.81,116.04,113.08,105.43,82.83,81.20,56.33.
[0152] (3-Fluoroazetidin-1-yl)(1-(2-fluoropyridin-4-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl)methanone (41). LCMS: R T =2.157min,>98% at 215 and 254nm, m / z=315.0[M+H] + ; 1 H NMR(499MHz, CDCl3)δ8.45(d,J=33.8Hz,2H),8.07(d,J=7.9Hz,1H),7.47–7.34(m,1H),7.28 (q,J=15.8,10.9Hz,2H),6.99(s,1H),5.41(dtt,J=56.3,6.3,3.4Hz,1H),4.67–4.20(m,5H). 13 CNMR (126MHz, CDCl3) δ162.12,162.10,158.77,156.77,149.26,146.86,136.60,136.53,130.64,130.56,13 0.23,124.07,124.04,120.91,120.77,119.15,118.17,116.45,116.27,106.22,99.98,82.82,81.18,29.72.
[0153] (1-(3,5-difluoro-4-methoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)(3-fluoroazetidin-1-yl)methanone (42). LCMS: R T =2.456min,>98% at 215 and 254nm, m / z=362.0[M+H] + ; 1H NMR (499MHz, CDCl3) δ8.47 (dd, J=4.7, 1.5Hz, 1H), 8.05 (dd, J=7.9, 1.6Hz, 1H), 7.23 (dd, J=7.9, 4.6Hz, 1H ),7.05(d,J=8.2Hz,2H),6.89(s,1H),5.41(ddt,J=56.4,6.1,2.9Hz,1H),4.69–4.21(m,5H),4.08(s,3H). 13 C NMR (126MHz, CDCl3) δ162.04,162.02,156.27,156.21,154.29,154.23,149.32,146.86,136.40,131.18,13 0.62,130.27,119.07,118.12,112.43,112.38,112.28,112.23,106.05,82.81,81.17,61.89,61.86,61.84.
[0154] (1-(3,4-Dichlorobenzyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)(3-fluoroazetidine-1-yl)methanone (43). To a solution of E (0.015 g; 0.068 mmol) in DMF (2.0 mL) was added 4-(bromomethyl)-1,2-dichlorobenzene (0.017 g; 0.082 mmol), Cs2CO3 (0.044 g; 0.14 mmol), and then heated at 120 °C for 1 h in a microwave reactor. After cooling, the solution was partitioned between EtOAc and saturated NaCl. The organic layer was separated, dried (MgSO4), concentrated, and purified by silica gel flash chromatography (using silica gel / DCM dry loading) with a gradient of 0-70% EtOAc:hexanes to give the corresponding target compound 43. LCMS: R T =2.853 min, >98% at 215 and 254 nm, m / z=378.0 [M+H] + ; 1 H NMR (499MHz, CDCl3) δ8.51 (dd, J=4.7, 1.6Hz, 1H), 8.02 (dd, J=7.9, 1.6Hz, 1H), 7.33 (dd, J=5.2, 3.1Hz, 2H), 7.20 (dd, J=7.9 ,4.7Hz,1H),7.11(dd,J=8.2,2.1Hz,1H),6.74(s,1H),5.90(s,2H),5.34(ddq,J=56.6,6.3,3.2Hz,1H),4.59–4.22(m,5H). 13C NMR (126MHz, CDCl3) δ163.13,148.44,146.29,139.06,132.34,131.24,130.51, 130.33,129.47,128.42,127.08,118.73,117.46,105.05,82.82,81.19,45.12.
[0155] Bioassay data
[0156] Example 2: In vitro PDE4 inhibition studies.
[0157] In vitro IC of compound 8 against PDE4 50 Sure:
[0158] IC of Compound 8 against PDE4 isoforms 50 Values are determined by BPS Bioscience (San Diego). Briefly, the coating protein (PDE4 isoform) was added to the plate in a volume of 50 μl (2-5 ng / μl) and overnight at 4°C. The next day, compound 8 was added to the coated plate at different concentrations, followed by the corresponding biotinylated binding partner. The reaction was incubated at room temperature for 2 hours. Binding assays were performed in duplicate at each concentration, and the plate was read using a Synergy 2BioTek plate reader. Luminescence data was analyzed using Graphpad Prism. The percentage of inhibition was determined by normalizing the data to negative control wells (uncoated wells treated with biotinylated ligands, set to 100% inhibition) and positive control wells (coated wells treated with biotinylated ligands in the absence of any inhibitor, set to 0% inhibition). The data for reference compounds or antibodies were included as controls for inhibition. The results are in Table B below. "ND" means that the compound has not been tested.
[0159] Table B
[0160]
[0161]
[0162] Example 3: Cell-based growth inhibition assay.
[0163] In vitro detection of the EC of compound 8 50 :
[0164] HEK293 cells were cultured in growth medium (10% fetal bovine serum, 1% Pen-Strep, 1% non-essential amino acids, 1 mM sodium pyruvate) and seeded into 96-well microplates at 30,000 cells / well. The cells were incubated overnight at 37°C and 5% CO2. The next day, cells were transfected with PDE4B1 expression vector, CRE luciferase reporter gene and control Renilla luciferase vector using Lipofectamine 2000 and Opti-MEM for 6 h. The culture medium was removed, and the cells were given test compounds or controls in 50 μl of fresh growth medium and incubated overnight. The next day, forskolin was added to 5 μl of growth medium and the wells were stimulated for 5-6 h at a final concentration of 10 μM. After treatment, a dual luciferase assay was performed using the BPS Bioscience dual luciferase assay system; 55 μl of firefly luciferase reagent per well was added to measure firefly luminescence. Subsequently, 55 μl / well of Renilla luciferase reagent was added to measure Renilla luminescence. Cell-based assays were performed in triplicate at each concentration. In order to obtain the normalized luciferase activity of the CRE reporter gene, background luminescence was subtracted, and then the ratio of the firefly luminescence from the CRE reporter gene to the Renilla luminescence from the control Renilla luciferase vector was calculated. The normalized luciferase activity data was analyzed, and EC was determined by causing the concentration of half-maximum activity percentage. 50 value.
[0165] Compared to apremilast, a PDE4 inhibitor approved for the treatment of psoriasis and psoriatic arthritis, compound 8 showed a ten-fold lower EC for PDE4B inhibition. 50 , the results are presented in Table C below.
[0166] Table C
[0167]
[0168] Example 4: Macrophage inhibition studies.
[0169] Bone marrow-derived macrophages were either unstimulated (-) or pretreated with the indicated concentrations of the well-characterized PDE4 inhibitor rolipram or the compound of interest (1 μM or 10 μM) for 30 min prior to LPS (100 ng / ml; A) or Pam3Cys (10 μg / ml; B). After 24 h of treatment, conditioned media were collected for quantification of TNF-α expression by ELISA. Results are reported as the mean (± SD) of 3 independent replicates per treatment and repeated in two separate experiments. *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001; one-way ANOVA and Dunnett's multiple comparison post hoc analysis.
[0170] Preparation of mouse bone marrow-derived macrophages and evaluation of PDE4 inhibitors on the pro-inflammatory activity of macrophages
[0171] As previously described, macrophages were expanded from the bone marrow of C57BL / 6 mice. Briefly, the bone marrow was flushed with sterile RPMI-1640 serum-free medium and cultured in RPMI-1640 containing 10% FBS, penicillin / streptomycin / amphotericin, and 5% conditioned medium from L929 fibroblasts as a source of macrophage colony stimulating factor (M-CSF). After a 6-day expansion period, macrophages were harvested and plated at 5×10 4 Cells / well were plated into 96-well plates. The next day, macrophages were pretreated with various concentrations of rolipram or the novel PDE4 inhibitor described in this report (1 μM or 10 μM) for 30 min before stimulation with LPS (100 ng / ml) or Pam3Cys (10 μg / ml). After 24 h of treatment, TNF-□ release from the conditioned medium was assessed by enzyme-linked immunosorbent assay (ELISA). Controls included unstimulated macrophages or cells exposed to PDE4 inhibitors alone.
[0172] Since PDE4 inhibitors have well-documented anti-inflammatory properties, the ability of these compounds to inhibit pro-inflammatory activity of macrophages was investigated by measuring the production of the classic pro-inflammatory cytokine TNF-α ( Figure 1 Two well-characterized pro-inflammatory stimuli, lipopolysaccharide (LPS) and a synthetic lipopeptide (Pam3Cys), were tested, representing typical bacterial ligands for Toll-like receptors 4 and 2 (TLR4 and TLR2), respectively. All tested compounds showed the same or better effects than the well-characterized PDE4 inhibitor rolipram ( Figure 1 ) inhibited TNF-α production by mouse bone marrow-derived macrophages to a degree that was not significantly different from that of the control group. For LPS-induced TNF-α release, a dose-dependent response was observed, with higher concentrations being ineffective across the entire compound group ( Figure 1 A), which has been reported in the case of other PDE4 inhibitors. When macrophages were stimulated with Pam3Cys, a similar dose response was observed for some compounds ( Figure 1 B); however, across the entire class of compounds, cytokine production was significantly reduced. When tested individually, none of the compounds elicited TNF-α production (data not shown). In summary, these findings support the biological effects of the target compounds, which mimic the anti-inflammatory effects of the well-characterized PDE4 inhibitor rolipram.
[0173] Example 5: Cocaine studies in mice.
[0174] Locomotor analysis: WT mice (both sexes, n=6-8) were divided into four groups receiving different treatments: (1) vehicle + saline; (2) vehicle + cocaine; (3) compound 8 + saline; and (4) compound 8 + cocaine. Cocaine was administered at 20 mg / kg (ip), and compound 8 was used at two different doses of 5 mg / kg or 10 mg / kg (ip). Compound 8 was first injected into the mice, and cocaine was administered 30 min later. To study the effect of compound 8 on acute locomotor responses, mice were placed in an open field apparatus (Truescan, Coulbourn Instruments) immediately after cocaine injection to detect locomotor activity for 45 min. The TruScan infrared activity system consists of a transparent arena with infrared sensors located on a ring 3 cm above ground level. There are 16 light beams spaced 1 inch apart on the sensor ring, which are used to detect the movement of the mice. These data will be automatically relayed to a PC computer and interpreted by the software. To investigate the effect of compound 8 on locomotor sensitization, mice were repeatedly injected with compound 8 and cocaine for 7 consecutive days, and locomotor responses were recorded every other day.
[0175] Self-administration:
[0176] (a) Surgical procedure: A permanent indwelling catheter (Plastics one) was implanted in the right jugular vein of WT mice (10-12 weeks, both sexes) under a combination of ketamine hydrochloride (100 mg / mg, ip) and xylazine (10 mg / mg, ip) anesthesia. The catheter was tied to the vein with surgical silk and passed subcutaneously to the back of the mouse, where it was fixed to a small plastic base (26G, Plastics One Company). After surgery, the catheter was flushed daily with heparin (30 IU / ml) to avoid clotting. Mice were allowed to recover in their home for at least 7 days before the start of the experiment.
[0177] (b) Establishment of cocaine self-administration mice: Mice were placed individually in a sound attenuated chamber (Coulbourne Instrument) to be trained to self-administer cocaine (1.0 mg / kg / infusion). Mice were reinforced by intravenous delivery of cocaine over 5 seconds with 20 μl of solution to nose prick the cue-paired (active) sensor, whereas nose prick to the inactive sensor did not produce results. A 15-second pause period followed each drug injection. All responses were automatically recorded using a computer interface and Graphic State Notation 4 software (Coulbourne Instrument). Mice were trained to self-administer cocaine in one daily session under a fixed ratio 1 (FR1) schedule. Each session lasted a maximum of 2 h, or until mice received 30 cocaine infusions to avoid overdose. The acquisition period was 7-10 days to help the mice establish stable cocaine self-administration according to the following criteria: (1) the ratio of active nose pricks to inactive nose pricks was higher than 2:1; (2) the minimum infusion of cocaine was more than 10 times; and (3) the variation of cocaine intake for three consecutive days was less than 20%. After cocaine intake was established, mice were subjected to cocaine self-administration for another week according to the FR1 schedule (daily 2h dosing period, 1.0 mg / kg / infusion). Mice were flushed before and after each dosing period and after the last dosing period, and ketamine was administered to the mice to confirm the patency of the catheter setting.
[0178] (c) Effects of Compound 8 on cocaine-mediated seeking and intake behaviors. Compound 8 / vehicle was injected into cocaine self-administered mice (ip), and 30 min later the mice were placed in the chamber for 2 h on a FR1 schedule. The number of active nose pricks and cocaine infusions was recorded. Mice injected with vehicle were used as controls.
[0179] Compound 8 significantly reduced cocaine-mediated seeking and intake behaviors in mice ( Figure 2 ), and inhibited cocaine-induced hyperlocomotion, whereas compound 8 alone did not show any increase ( Figure 3 ).
[0180] In view of the many possible embodiments to which the principles of the present disclosure may be applied, it should be recognized that the illustrated embodiments are merely examples and should not be taken as limiting the scope of the invention.
Claims
1. A compound having the structure of formula (I) or a pharmaceutically acceptable salt thereof: in X, Y and Z are each independently CR3; R is for C 0-6 Alkylene-phenyl or C 0-6 Alkylene-6-membered heteroaryl, the phenyl or 6-membered heteroaryl is unsubstituted or substituted by 1-3 R4; R1 and R2 together with the nitrogen atom to which they are attached form a 3-10 membered heterocycloalkyl ring containing 0-2 additional ring heteroatoms independently selected from N, O and S, wherein the heterocycloalkyl is unsubstituted or substituted with 1-3 R6; Each R3 is independently H or C 1-6 alkyl; Each R4 is independently C 1-6 Alkyl, halogen, CF3, CN, or OC 1-6 Alkyl; and R6 is independently C 1-6 Alkyl, halogen, CF3, CN, OH, or OC 1-6 alkyl.
2. The compound or salt of claim 1, wherein X, Y and Z are each CH.
3. The compound or salt according to claim 1, wherein R is C 0-6 Alkylene-phenyl.
4. The compound or salt of claim 1, wherein R is phenyl.
5. The compound or salt of claim 1, wherein R is substituted with 1 to 3 R4.
6. The compound or salt according to claim 5, wherein R is substituted by 2 R4.
7. The compound or salt according to claim 5, wherein R is substituted by 3 R4.
8. The compound or salt according to claim 1, wherein each R4 is independently C 1-6 Alkyl, OC 1-6 Alkyl, halogen or CN.
9. The compound or salt of claim 8, wherein at least one R4 is fluoro.
10. The compound or salt of claim 8, wherein at least one R4 is chloro.
11. The compound or salt of claim 8, wherein at least one R4 is methyl.
12. The compound or salt of claim 8, wherein at least one R4 is CN or OMe.
13. The compound or salt according to claim 1, wherein R is 14. The compound or salt according to claim 13, wherein R is 15. The compound or salt of claim 1, wherein R is dichlorophenyl.
16. The compound or salt of claim 1, wherein R1 and R2 together with the atoms to which they are attached form a 4-membered heterocycloalkyl ring.
17. The compound or salt of claim 16, wherein the heterocycloalkyl ring is unsubstituted.
18. The compound or salt of claim 16, wherein the heterocycloalkyl ring is substituted with 1-3 R6.
19. The compound or salt thereof according to claim 18, wherein R6 is halogen or CF3.
20. The compound or salt of claim 19, wherein at least one R6 is halogen.
21. The compound or salt of claim 20, wherein each R6 is halogen.
22. The compound or salt of claim 18, wherein R6 is fluoro.
23. The compound or salt of claim 19, wherein at least one R6 is CF3.
24. The compound or salt of claim 16, wherein N(R1)(R2) is 25. The compound or salt of claim 1, wherein N(R1)(R2) is 26. The compound or salt according to claim 1, selected from compounds 6-12, 14, 15, 25, 30, 37, 38, 42 and 43 shown below:
27. A pharmaceutical formulation comprising a compound or salt according to any one of claims 1 to 26 and a pharmaceutically acceptable excipient.
28. Use of a compound or salt according to any one of claims 1 to 26 or a pharmaceutical formulation according to claim 27 in the preparation of a medicament for treating, inhibiting or preventing psoriatic arthritis, plaque psoriasis or cocaine addiction in a subject.
29. The use according to claim 28, wherein the medicament is for treating, suppressing or preventing cocaine addiction.
